The Use of FOLFOX4 Regimen in Stage IV Cervical Cancer: A Pilot Study

Abstract

Objective: To evaluate the efficacy and safety of FOLFOX4 (oxaliplatin/5FU/Leucovorin) for the treatment of metastatic cervical cancer. Methods: All patients were designed to receive the FOLFOX4 regimen (Oxaliplatin (Eloxatin ® ) 85 mg/m 2 D1, 5-Fluorouracil 400 mg/m 2 IV push D1-2, 5-Fluorouracil 600 mg/m 2 IV drip in 22 hours D1-2 and Folinic acid 200 mg/m 2 IV push in D1-2). The treatment responsiveness and toxicities were evaluated. Results: Thirty patients from January 2010-December 2012 were enrolled into the study. The mean age was 51 years old. Nine patients (31%) achieved objective response. At the mean follow-up time of 13 months, the one-year progression-free and overall survival rates were 20.7% and 65.5%, respectively. The most common grade 3 adverse event reported in this study was anemia (36.7%), thrombocytopenia (16.7%) and fatigue (16.7%). Conclusions: FOLFOX4 regimen in metastatic cervical cancer is feasible.

Pan-Cancer, Genome-Scale Metabolic Network Analysis of over 10,000 Patients Elucidates Relationship between Metabolism and Survival

“…This pattern suggests that 5-FU-based therapies like FOLFIRINOX could be beneficial in these patient populations. Indeed, there is evidence that suggests this is the case [41][42][43][44][45].…”